Return to: Department of Medicine : Medical School : Academic Health Center : myU : U of M Home

Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
Whats Inside
Center for Lung Science and Health

Conferences

Contact Us

Faculty

Fellowship Program

Make a Gift

NHLBI Training Grant Program

Outpatient Clinic Information

Recent Achievements

Research

 

PACCHome

Home > Faculty > Timothy Whelan, MD

Printer-friendly version   Mail this page to a friend

Timothy Whelan, MD


 Dr. Timothy Whelan

Assistant Professor of Medicine
Contact Information

BA - Lafayette College, Easton, PA in English and Biology (cum laude)
MD - State University of New York at Buffalo (magna cum laude)
Internal Medicine Training - University of Colorado Health Sciences Center
Pulmonary/Critical Care Training - University of Washington

My previous pulmonary and critical care training has provided me with the expertise to care for the complex health care issues of patients with advanced lung disease and/or patients who have undergone lung transplantation.  While at the University of Washington, I actively participated in all aspects of lung transplantation from the medical evaluation of the patient pre-transplant to donor procurement and perioperative care and, finally, post-operative management of the lung transplant recipient.  In addition, I gained experience caring for patients with interstitial lung disease.  I hope to further pursue these interests here in Minnesota.  First and foremost, I think of myself as a clinician who can provide knowledgeable, compassionate care to patients who have advanced lung disease.  While doing so, I hope to help develop an interstitial lung disease clinic at the University of Minnesota that will allow us to deliver state-of-the-art care to the patient, as well as serve as a foundation for ongoing clinical trials in interstitial lung disease.  I also have an active interest in determining which factors play an important outcomes role in post lung transplantation.  In particular, I am involved in clinical outcomes research that uses information from the International Society of Heart and Lung Transplant Registry as well as information from our own database at University of Minnesota.

 Selected Recent Publications.

Alawali R, Whelan T, Bajwa R, Hodges T.  Lung transplantatoin and interstitial lung disease.  Curr Opin Pulm Med. 2005, 11: 461-466.

Whelan TPM, Dunitz JM, Kelly RF, Edwards LB, Herrington CS, Hertz MI, Dahlbert PS.  Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis.  J Heart Lung Transplant 2005, 24(9): 1269-1274.

Barr ML, Kawut SM, Whelan TP, Grigis R, Bottcher H, Sonett J, Vigneswaran W, Follette DM, Corris PA.  Report of the International Society for Heart and Lung Transplantaton Working Group on Primary Lung Graft Dysfunction: IV, Recipient-related risk factors and markers.  J Heart Lung Transplant.   2005, 24(10): 1468-1482.

Whelan TPM, Hertz MI.  Pulmonary allograft rejection in lung transplantation.  Clin Chest Med.   2005, 26(4): 599-612.

Whelan TPM.  Lung transplantation: a therapy for interstitial lung disease?  Current Opinion in Organ Transplantation.  2006 October; 11(5):502-07.

Kempainen RR, Savik K, Whelan TP, et al.  High prevalence of proximal and distal gastroesophageal reflux disease in advanced COPD.  Chest   2007, 131:1666-1671.

Whitson BA, Prekker, ME, Herrington CS, Whelan TP, Radosevich DM, Hertz MI, Dahlberg PS.  Primary graft dysfunction and long-term pulmonary function after lung transplantation.  J Heart Lung Transplant 2007; 26(10):1004-11.

Current Research Projects and Grant Support

Genzyme Phase I study of the safety of GC-1008 in patients with idiopathic pulmonary fibrosis: An open label investigation of an humanized antibody to  TGF-beta.  (2006-present) Principal Investigator

Actelion BUILD 3: Effects of bosentan on morbidity and mortality in patients with idiopathic pulmonary fibrosis- a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven phase III study.  (2006 to present) Principal Investigator

InterMune Protocol PIPF—004: A randomized, double-blind, placebo-controlled, Phase 3, three-arm study of the safety and efficacy of Pirfenidone in patients with idiopathic pulmonary fibrosis (2006 – present) Principal Investigator

Effect of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis at the University of Minnesota (2006 - present) Principal Investigator – Funded in part by a gift from David and Anne Amato

InterMune INSPIRE Trial: A randomized, double-blind, placebo-controlled multinational Phase 3 three-arm study of the safety and efficacy of 200 mg subcutaneous interferon gamma—1b in patients with idiopathic pulmonary fibrosis (August 2004—2007).  Principal Investigator

A Phase III, randomized, double-blind comparison of oral Valganciclovir and placebo for prevention of CMV infection after lung transplantation. Co-investigator

In collaboration with Cynthia Herrington MD, Division of Cardiothoracic and Vascular Surgery, University of Minnesota:

Donor management: Factors impacting on successful lung procurement (2006-present) Co-investigator

Factors predisposing patients to development of primary graft dysfunction post-transplant. Co-investigator

Donor management: Donor factors impacting on lung transplant recipient outcome (2006-present), Co-investigator

Last Updated 4/11/2008


Feedback | Notice of Privacy Practices


 
The University of Minnesota is an equal opportunity educator and employer.